66 Biggest Movers From Yesterday
Gainers
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share.
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
F-star Therapeutics Reports Granted Composition Of Matter Patent For Its Novel Second-Gen STING Agonist, SB 11285
F-star Therapeutics, Inc. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
F-star Therapeutics Announces Collaboration With MSD To Evaluate FS120 In Combination With KEYTRUDA
F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
F-star Therapeutics Says Early Data From SB 11285 ‘Encourage Further Dose Escalation’
F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of
Why F-Star Therapeutics Shares Are Trading Higher Today
F-Star Therapeutics (NASDAQ: FSTX) shares are trading higher after the company entered into an exclusive licensing agreement with AstraZeneca (NASDAQ: AZN) for its STING Inhibitors.